OMAHA, Neb., March 5 /PRNewswire-FirstCall/ -- Transgenomic, Inc. , a leading global biotechnology company, announced today its Molecular Laboratory has received notification from the state of California it can begin offering its services in the state. Transgenomic expects to begin marketing their Molecular Laboratory services, including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and Inherited Diseases, to physicians in California immediately. Transgenomic also boasts a comprehensive portfolio of cytogenetics, FISH, IHC and histology diagnostics.
This California certification reinforces previous certifications awarded to Transgenomic’s state-of-the-art testing facility. Transgenomic’s Molecular Laboratory is a Good Laboratory Practices (GLP) compliant environment, is certified under the Clinical Laboratory Improvement Amendment (CLIA) as a high complexity lab, and is accredited by CAP (College of American Pathologists).
“The state of California represents the largest market opportunity in the United States for Transgenomic’s Molecular Laboratory testing services,” said Craig Tuttle, President and Chief Executive Officer of Transgenomic. “The state of California follows a rigorous certification process. Completing our California license not only allows us to penetrate this large market for our testing services but it is also a testament to the high quality standards of our laboratory services business.”
About Transgenomic
Transgenomic is a global biotechnology company that provides unique products and services for automated high sensitivity genetic variation and mutation analysis. Their offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of Pharmacogenomics and personalized medicine. Specific offerings include WAVE(R) DHPLC Systems, related consumables and assay kits, Cytogenetics automated systems, and Transgenomic Pharmacogenomics and Reference Laboratory Services. Transgenomic Pharmacogenomics and Laboratory Services utilize their technology and expertise to provide a menu of mutation scanning tests for over 700 cancer-associated genes and more than 60 validated diagnostic tests to meet the needs of pharmaceutical and biotech companies, research and clinical laboratories, physicians and patients. For more information about the innovative systems, products and services offered by Transgenomic, please visit: www.transgenomic.com.
Cautionary Statements
Certain statements in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management’s current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in reports to the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release.
CONTACT: Debra Schneider, Chief Financial Officer of Transgenomic, Inc.,
+1-402-452-5400, investorrelations@transgenomic.com
Web site: http://www.transgenomic.com/
